Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update

Diabetes mellitus and heart failure are two diseases that are commonly found together, in particular in older patients. High blood glucose has a detrimental effect on the cardiovascular system, and worse glycemic control contributes to the onset and the recrudesce of heart failure. Therefore, any sp...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Pharmaceuticals (Basel, Switzerland) Ročník 17; číslo 11; s. 1419
Hlavní autori: Profili, Nicia I., Castelli, Roberto, Gidaro, Antonio, Manetti, Roberto, Maioli, Margherita, Delitala, Alessandro P.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Switzerland MDPI AG 01.11.2024
MDPI
Predmet:
acute heart failure
Autophagy
Cardiac arrhythmia
Cardiovascular disease
Care and treatment
chronic heart failure
Complications and side effects
Diabetes
Diuretics
Dosage and administration
Ejection fraction
Glucose
Glycosylated hemoglobin
Health aspects
Heart failure
Hypoglycemic agents
Inflammation
Kidney diseases
Measurement
Mortality
Na+-glucose cotransporter-2 inhibitors
Older people
Oxidative stress
Prevention
Review
Risk factors
SGLT2i
Type 2 diabetes
Italy
cardiovascular disease
chronic heart failure
acute heart failure
Na+-glucose cotransporter-2 inhibitors
SGLT2i
diabetes
ISSN:1424-8247, 1424-8247
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Diabetes mellitus and heart failure are two diseases that are commonly found together, in particular in older patients. High blood glucose has a detrimental effect on the cardiovascular system, and worse glycemic control contributes to the onset and the recrudesce of heart failure. Therefore, any specific treatment aimed to reduce glycated hemoglobin may, in turn, have a beneficial effect on heart failure. Sodium-glucose cotransporter-2 inhibitors have been initially developed for the treatment of type 2 diabetes mellitus, and their significant action is to increase glycosuria, which in turn causes a reduction in glucose blood level and contributes to the reduction of cardiovascular risk. However, recent clinical trials have progressively demonstrated that the glycosuric effect of the sodium-glucose cotransporter-2 inhibitors also have a diuretic effect, which is a crucial target in the management of patients with heart failure. Additional studies also documented that sodium-glucose cotransporter-2 inhibitors improve the therapeutical management of heart failure, independently by the glycemic control and, therefore, by the presence of diabetes mellitus. In this review, we analyzed studies and trials demonstrating the efficacy of sodium-glucose cotransporter-2 inhibitors in treating chronic and acute heart failure.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1424-8247
1424-8247
DOI:10.3390/ph17111419